{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Crescita Reports Third Quarter 2020 Results - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"W48r1KThnW\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/\">Crescita Reports Third Quarter 2020 Results<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/embed\/#?secret=W48r1KThnW\" width=\"600\" height=\"338\" title=\"&#8220;Crescita Reports Third Quarter 2020 Results&#8221; &#8212; Market Newsdesk\" data-secret=\"W48r1KThnW\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire Strong Ending Cash Balance of $13.9M LAVAL, QC, Nov. 12, 2020 \/CNW Telbec\/ Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (&#8220;Crescita&#8221; or the &#8220;Company&#8221;), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research &amp; development (&#8220;R&amp;D&#8221;) and manufacturing capabilities,\u00a0today reported its financial results for the third quarter ended September 30, 2020 (&#8220;Q3-F2020&#8221;). \u00a0All amounts presented are in thousands of Canadian dollars (&#8220;CAD&#8221;) unless otherwise noted. Financial Highlights \u00a0\u2013 Q3-F2020 vs. Q3-F2019 Revenue was $7,301 compared to $4,906, an increase of $2,395; In Q3-F2020, the Company amended its licensing agreement with commercial partner Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;) for Pliaglis\u00ae in the U.S. and received a total of $5,151(US$3,855). Revenue was recorded as follows: $4,483 (US$3,355) as licensing &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg"}